VWM
TEVA icon

Vermillion Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Vermillion Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-308
Closed -$9.28K – 2359
2026
Q1 		$9.28K Hold
308
– – ﹤0.01% 404
2025
Q4 		$9.61K Buy
308
+148
+93% +$3.65K ﹤0.01% 389
2025
Q3 		$3.23K Buy
+160
New +$2.81K ﹤0.01% 1342
2025
Q2 		– Sell
-308
Closed -$4.73K – 579
2025
Q1 		$4.73K Hold
308
– – ﹤0.01% 1119
2024
Q4 		$6.79K Buy
+308
New +$5.6K ﹤0.01% 369

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Vermillion Wealth Management's TEVA Position: Q2 2026 in Review

Vermillion Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 308 shares — an estimated $9.28K sold.

Vermillion Wealth Management first reported a position in TEVA in Q4 2024 and held it in 5 quarters. The position peaked at $9.61K in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Vermillion Wealth Management reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vermillion Wealth Management sold 308 Teva Pharmaceuticals shares in Q2 2026, an estimated $9.28K.
  • Vermillion Wealth Management first reported a position in Teva Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • Vermillion Wealth Management's Teva Pharmaceuticals position peaked at $9.61K in Q4 2025.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.